LXEO
NASDAQLexeo Therapeutics Inc.
Price$4.23-0.19 (-4.30%)
01:30 PM07:45 PM
News · 26 weeks46-70%
2025-12-142026-06-07
Mix2190d
- Insider7(33%)
- SEC Filings7(33%)
- Other6(29%)
- Leadership1(5%)
Latest news
25 items- INSIDERChief Operating Officer Otero Jose Manuel sold $6,606 worth of shares (1,302 units at $5.07), decreasing direct ownership by 0.99% to 130,088 units (SEC Form 4) (for withholding tax)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan sold $16,927 worth of shares (3,342 units at $5.06), decreasing direct ownership by 0.98% to 336,764 units (SEC Form 4) (for withholding tax)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- PRLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceNEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company ded
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECSEC Form 10-Q filed by Lexeo Therapeutics Inc.10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational HighlightsSUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform to be presented at ASGCT 2026 Appointed Laura Sepp-Lorenzino, Ph.D. to Board of Directors Cash, cash equivalents and investments of $227.6 million expected to provide operational runway into 2028 NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates ac
- INSIDERSEC Form 4 filed by Director Sepp-Lorenzino Laura4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sepp-Lorenzino Laura3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECSEC Form DEFA14A filed by Lexeo Therapeutics Inc.DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECSEC Form DEF 14A filed by Lexeo Therapeutics Inc.DEF 14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. "We're excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo's science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich ataxia (FA
- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- INSIDERSEC Form 4 filed by Townsend Richard Nolan4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECSEC Form 10-K filed by Lexeo Therapeutics Inc.10-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsSUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC) Annual Meeting demonstrate continued, encouraging efficacy and safety data across LX2006 and LX2020 programs Established research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapy using novel, localized routes of administration St
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- INSIDERChief Executive Officer Townsend Richard Nolan was granted 2,623 shares, increasing direct ownership by 0.67% to 395,106 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel was granted 5,930 shares, increasing direct ownership by 5% to 131,390 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- PRLexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to resha
- INSIDERChief Operating Officer Otero Jose Manuel sold $19,294 worth of shares (3,016 units at $6.40), decreasing direct ownership by 2% to 125,460 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan sold $64,924 worth of shares (10,173 units at $6.38), decreasing direct ownership by 3% to 392,483 units (SEC Form 4)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERAmendment: Chief Operating Officer Otero Jose Manuel sold $6,684 worth of shares (721 units at $9.27), decreasing direct ownership by 1% to 63,476 units (SEC Form 4)4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
LXEO FAQ
6 questionsWhere does LXEO stock trade?
Lexeo Therapeutics Inc. (LXEO) is listed on NASDAQ.What sector and industry is LXEO in?
Lexeo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Lexeo Therapeutics Inc. go public?
Lexeo Therapeutics Inc. (LXEO) completed its IPO in 2023.What are analysts saying about LXEO?
Lexeo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $2500.00 price target on 2025-12-18. Recent price targets range from $1900.00 to $3000.00.What companies are similar to LXEO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare LXEO side-by-side with any of them on Quantisnow.How can I track LXEO on Quantisnow?
Quantisnow aggregates Lexeo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LXEO to receive live email and push alerts on every new disclosure.